Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02864316 · ClinicalTrials.gov registry record · Phase 2
Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02864316 is a Phase 2 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 6 participants.
The verdict
NCT02864316, a Phase 2 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether Nivolumab is effective in the treatment of radiation-induced solid tumors.
Interventions
- DRUG Nivolumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-12 |
| Est. Completion | 2018-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02864316
The ClinicalTrials.gov registry entry for NCT02864316 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Nivolumab is the first listed.
NCT02864316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02864316 about?
NCT02864316 is a clinical study titled "Phase 2 Study of Nivolumab in Solid Tumors Induced by Prior Radiation Exposure". The purpose of this study is to determine whether Nivolumab is effective in the treatment of radiation-induced solid tumors.
What is the current status of trial NCT02864316?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2016-12. Estimated completion is 2018-09.
What interventions are being tested in trial NCT02864316?
The interventions under investigation include: Nivolumab (DRUG).
Who is sponsoring clinical trial NCT02864316?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.